Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation

dc.contributor.authorAzócar Gallardo, Jairo
dc.contributor.authorRamirez Campillo, Rodrigo
dc.contributor.authorAfonso, José
dc.contributor.authorSá, Mário
dc.contributor.authorGranacher, Urs
dc.contributor.authorGonzález Rojas, Luis
dc.contributor.authorOjeda Aravena, Alex
dc.contributor.authorGarcía García, José Manuel
dc.date.accessioned2023-06-13T17:03:31Z
dc.date.available2023-06-13T17:03:31Z
dc.date.issued2022-11
dc.descriptionIndexación: Scopus.es
dc.description.abstractMetformin, a drug widely used to treat insulin resistance, and training that combines aerobic and strength exercise modalities (i.e., concurrent training) may improve insulin sensitivity. However, there is a paucity of clinical trials investigating the effects of concurrent training, particularly on insulin resistance and fat oxidation in overweight and obese patients. Furthermore, only a few studies have compared the effects of concurrent training with metformin treatment. Therefore, the aim of this study was to examine the effects of a 12-week concurrent training program versus pharmaceutical treatment with metformin on maximum fat oxidation, glucose metabolism, and insulin resistance in overweight or obese adult patients. Male and female patients with insulin resistance were allocated by convenience to a concurrent training group (n = 7 (2 males); age = 32.9 ± 8.3 years; body mass index = 30 ± 4.0 kg·m−2) or a metformin group (n = 7 (2 males); age = 34.4 ± 14.0 years; body mass index = 34.4 ± 6.0 kg·m−2). Before and after the interventions, all participants were assessed for total body mass, body mass index, fat mass, fat-free mass, maximum oxygen consumption, maximal fat oxidization during exercise, fasting glucose, and insulin resistance through the homeostatic model assessment (HOMA-IR). Due to non-normal distribution of the variable maximal fat oxidation, the Mann–Whitney U test was applied and revealed better maximal fat oxidization (Δ = 308%) in the exercise compared with the metformin group (Δ = −30.3%; p = 0.035). All other outcome variables were normally distributed, and significant group-by-time interactions were found for HOMA-IR (p < 0.001, Δ = −84.5%), fasting insulin (p < 0.001, Δ = −84.6%), and increased maximum oxygen consumption (p = 0.046, Δ = 12.3%) in favor of the exercise group. Similar changes were found in both groups for the remaining dependent variables. Concurrent training seems to be more effective compared with pharmaceutical metformin treatment to improve insulin resistance and fat oxidation in overweight and obese adult patients with insulin resistance. The rather small sample size calls for more research in this area. © 2022 by the authors.es
dc.description.urihttps://www.mdpi.com/1660-4601/19/21/14331
dc.identifier.citationInternational Journal of Environmental Research and Public Health, Volume 19, Issue 21, November 2022, Article number 14331es
dc.identifier.doi10.3390/ijerph192114331
dc.identifier.issn1661-7827
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/50625
dc.language.isoenes
dc.publisherMDPIes
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.es
dc.subjectEndurance traininges
dc.subjectExercisees
dc.subjectHuman physical conditioninges
dc.subjectMuscle strengthes
dc.subjectMusculoskeletal and neural physiological phenomenaes
dc.subjectResistance traininges
dc.titleOverweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidationes
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Azocar_Overweight_and_obese_adult_patients.pdf
Tamaño:
940.48 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción: